James Shepherd

Summary

Affiliation: Royal Infirmary
Country: UK

Publications

  1. ncbi Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs
    James Shepherd
    Institute of Biochemistry, Royal Infirmary, Glasgow G4 0SF, UK
    Lancet 359:2271-3. 2002
  2. ncbi Preventing the next event in the elderly: the PROSPER perspective
    James Shepherd
    Department of Pathological Biochemistry, University Department of Pathological Biochemistry, Royal Infirmary, Glasgow, G4 0SF, Scotland, UK
    Atheroscler Suppl 4:17-22. 2003
  3. ncbi A prospective study of pravastatin in the elderly at risk: new hope for older persons
    James Shepherd
    Institute of Biochemistry, Royal Infirmary, University of Glasgow, Glasgow, Scotland
    Am J Geriatr Cardiol 13:17-24. 2004
  4. ncbi Does statin monotherapy address the multiple lipid abnormalities in type 2 diabetes?
    James Shepherd
    Department of Biochemistry, Royal Infirmary, Glasgow G4 OSF, Scotland, UK
    Atheroscler Suppl 6:15-9. 2005
  5. pmc Statins for primary prevention: strategic options to save lives and money
    James Shepherd
    Institute of Biochemistry, Royal Infirmary, Glasgow G4 0SF, Scotland, UK
    J R Soc Med 97:66-71. 2004
  6. ncbi Monotherapy vs combination therapy for dyslipidemia in the elderly
    James Shepherd
    University Department of Pathological Biochemistry, Royal Infirmary, Glasgow, Scotland, UK
    Am J Geriatr Cardiol 17:108-13. 2008
  7. ncbi Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
    James Shepherd
    University Department of Pathological Biochemistry, University of Glasgow, Royal Infirmary, Scotland, Glasgow, UK
    Lancet 360:1623-30. 2002
  8. doi Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study
    James Shepherd
    University of Glasgow, Glasgow, United Kingdom
    J Am Coll Cardiol 51:1448-54. 2008
  9. ncbi Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor
    Naveed Sattar
    Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland
    Diabetes 56:984-91. 2007
  10. ncbi Effect of pravastatin on the development of diabetes and adiponectin production
    Toshiyuki Takagi
    Department of Medicine and Pathophysiology, Graduate School of Frontier Bioscience, Graduate School of Medicine, Osaka University, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    Atherosclerosis 196:114-21. 2008

Collaborators

Detail Information

Publications55

  1. ncbi Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs
    James Shepherd
    Institute of Biochemistry, Royal Infirmary, Glasgow G4 0SF, UK
    Lancet 359:2271-3. 2002
  2. ncbi Preventing the next event in the elderly: the PROSPER perspective
    James Shepherd
    Department of Pathological Biochemistry, University Department of Pathological Biochemistry, Royal Infirmary, Glasgow, G4 0SF, Scotland, UK
    Atheroscler Suppl 4:17-22. 2003
    ..Therefore, PROSPER extends to elderly individuals the treatment strategy currently used in middle-aged people...
  3. ncbi A prospective study of pravastatin in the elderly at risk: new hope for older persons
    James Shepherd
    Institute of Biochemistry, Royal Infirmary, University of Glasgow, Glasgow, Scotland
    Am J Geriatr Cardiol 13:17-24. 2004
    ..These results demonstrate the benefits of pravastatin in primary and, particularly, secondary prevention in elderly populations and further support the benefits of statin therapy in high-risk elderly persons...
  4. ncbi Does statin monotherapy address the multiple lipid abnormalities in type 2 diabetes?
    James Shepherd
    Department of Biochemistry, Royal Infirmary, Glasgow G4 OSF, Scotland, UK
    Atheroscler Suppl 6:15-9. 2005
    ..In order to achieve improved outcomes in diabetes patients, it will be important to address other abnormalities in their lipid profiles, including elevated triglycerides and low HDL-C...
  5. pmc Statins for primary prevention: strategic options to save lives and money
    James Shepherd
    Institute of Biochemistry, Royal Infirmary, Glasgow G4 0SF, Scotland, UK
    J R Soc Med 97:66-71. 2004
  6. ncbi Monotherapy vs combination therapy for dyslipidemia in the elderly
    James Shepherd
    University Department of Pathological Biochemistry, Royal Infirmary, Glasgow, Scotland, UK
    Am J Geriatr Cardiol 17:108-13. 2008
    ....
  7. ncbi Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
    James Shepherd
    University Department of Pathological Biochemistry, University of Glasgow, Royal Infirmary, Scotland, Glasgow, UK
    Lancet 360:1623-30. 2002
    ..Our aim was to test the benefits of pravastatin treatment in an elderly cohort of men and women with, or at high risk of developing, cardiovascular disease and stroke...
  8. doi Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study
    James Shepherd
    University of Glasgow, Glasgow, United Kingdom
    J Am Coll Cardiol 51:1448-54. 2008
    ..This subanalysis of the TNT (Treating to New Targets) study investigates the effects of intensive lipid lowering with atorvastatin in patients with coronary heart disease (CHD) with and without pre-existing chronic kidney disease (CKD)...
  9. ncbi Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor
    Naveed Sattar
    Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland
    Diabetes 56:984-91. 2007
    ....
  10. ncbi Effect of pravastatin on the development of diabetes and adiponectin production
    Toshiyuki Takagi
    Department of Medicine and Pathophysiology, Graduate School of Frontier Bioscience, Graduate School of Medicine, Osaka University, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    Atherosclerosis 196:114-21. 2008
    ..47+/-0.33 microg/ml, p=0.0003). Taken together, our findings suggest that pravastatin may have beneficial effects on adipose tissue, which may partly explain the reduction of the development of diabetes by pravastatin treatment...
  11. ncbi Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program
    James Shepherd
    Department of Pathological Biochemistry, University of Glasgow, Glasgow, UK
    Cardiology 107:433-43. 2007
    ....
  12. ncbi C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
    Naveed Sattar
    Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland, UK
    Circulation 115:981-9. 2007
    ..The role of C-reactive protein (CRP) in predicting vascular events and response to statin therapy remains uncertain. Additional large prospective studies are required...
  13. ncbi Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study
    Scott W Brouilette
    Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
    Lancet 369:107-14. 2007
    ..Inter-individual differences in biological ageing could affect susceptibility to coronary heart disease. Our aim was to determine whether mean leucocyte telomere length is a predictor of the development of coronary heart disease...
  14. ncbi Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS
    Olga A Iakoubova
    Celera Inc, 1401 Harbor Bay Parkway, Alameda, CA 94502, USA
    Arterioscler Thromb Vasc Biol 26:2763-8. 2006
    ..Because the myeloid IgA Fc receptor encoded by FCAR mediates inflammation, we hypothesized that the FCAR Asp92Asn polymorphism is associated with risk of MI and that this risk would be modified by pravastatin...
  15. ncbi Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
    Prakash Deedwania
    Veterans Affairs Central California Healthcare System and University of California San Francisco School of Medicine, San Francisco, CA, USA
    Lancet 368:919-28. 2006
    ....
  16. ncbi Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study
    James Shepherd
    Department of Vascular Biochemistry, Royal Infirmary, Glasgow G4 OSF, U K
    Diabetes Care 29:1220-6. 2006
    ..The objective of our study was to investigate whether similar benefits of high-dose intensive atorvastatin therapy can be achieved in patients with CHD and diabetes...
  17. ncbi Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
    Chris J Packard
    Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland
    Circulation 112:3058-65. 2005
    ..We assessed the role of plasma lipoproteins as predictors of risk and of treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)...
  18. ncbi Long-term follow-up of the West of Scotland Coronary Prevention Study
    Ian Ford
    Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom
    N Engl J Med 357:1477-86. 2007
    ..9 to 5.5% (P<0.001) in the treatment group. Extended follow-up data were obtained for approximately 10 years after completion of the trial...
  19. ncbi Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study
    James Shepherd
    Department of Vascular Biochemistry, University of Glasgow, G31 2ER, UK
    Clin J Am Soc Nephrol 2:1131-9. 2007
    ..This subanalysis of the Treating to New Targets study investigated how intensive lipid lowering with 80 mg of atorvastatin affects renal function when compared with 10 mg in patients with coronary heart disease...
  20. ncbi Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population
    Eliana Polisecki
    Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA 02111, USA
    Atherosclerosis 200:95-101. 2008
    ..Our data support the concept that the rare allele of the R46L SNP at the PCSK9 locus significantly lowers LDL C, but does not greatly reduce CHD risk in an elderly population with a high prevalence of cardiovascular disease...
  21. ncbi Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER
    Eliana Polisecki
    Cardiovascular Research and Lipid Metabolism Laboratories, Friedman School of Nutrition Science and Policy, Tufts University School of Medicine and the Jean Mayer USDA Human Nutrition Research Center at Tufts University, Boston, MA USA
    Atherosclerosis 200:109-14. 2008
    ..Our data indicate that genetic variation at the LDLR locus can affect baseline lipids, response to pravastatin, and CVD risk in subjects placed on statin treatment...
  22. doi Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials
    Olga A Iakoubova
    Celera, Inc, Alameda, California 94502, USA
    J Am Coll Cardiol 51:435-43. 2008
    ....
  23. ncbi Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 28:562-7. 2008
    ..The purpose of this study was to investigate the association between the Ala227Pro polymorphism in the ADAMTS1 metalloproteinase gene and coronary heart disease and benefit from statin therapy in 2 independent cohorts...
  24. ncbi Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein
    Paul M Ridker
    JUPITER Coordinating Center, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 100:1659-64. 2007
    ..In conclusion, as 20 mg of rosuvastatin can reduce LDL cholesterol by up to 50%, JUPITER will also provide crucial safety data for several thousand patients who should achieve LDL cholesterol levels<50 mg/dl on a long-term basis...
  25. doi Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery
    Sanjiv J Shah
    Division of Cardiology, San Francisco General Hospital, University of California, San Francisco, California 94110, USA
    J Am Coll Cardiol 51:1938-43. 2008
    ....
  26. doi Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies
    Naveed Sattar
    Faculty of Medicine, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
    Lancet 371:1927-35. 2008
    ..We investigated to what extent metabolic syndrome and its individual components were related to risk for these two diseases in elderly populations...
  27. ncbi Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease
    James Shepherd
    University of Glasgow, United Kingdom
    Mayo Clin Proc 83:870-9. 2008
    ....
  28. ncbi Association between apolipoprotein E4 and cognitive decline in elderly adults
    Chris J Packard
    Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland
    J Am Geriatr Soc 55:1777-85. 2007
    ..To determine the influence of apolipoprotein E on cognitive decline in a cohort of elderly men and women...
  29. pmc The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
    Jill Belch
    Institute of Cardiovascular Research, University of Dundee, Ninewells Hospital, Dundee DD1 9SY
    BMJ 337:a1840. 2008
    ..To determine whether aspirin and antioxidant therapy, combined or alone, are more effective than placebo in reducing the development of cardiovascular events in patients with diabetes mellitus and asymptomatic peripheral arterial disease...
  30. ncbi Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors
    Frank M Sacks
    Nutrition Department, Harvard School of Public Health F M S, Boston, Mass 02115, USA
    Circulation 105:1424-8. 2002
    ..We conducted exploratory analyses of participant characteristics, lipid risk factors, and risk reduction in this group...
  31. ncbi Effect of pravastatin on cardiovascular events in people with chronic kidney disease
    Marcello Tonelli
    Division of Nephrology, University of Alberta, 7 129 Clinical Science Building, 8440 112 St, Edmonton, Alberta T6G 2G3, Canada
    Circulation 110:1557-63. 2004
    ..The objective of this analysis was to determine whether pravastatin reduced the incidence of cardiovascular events in people with or at high risk for coronary disease and with concomitant moderate CKD...
  32. ncbi Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C
    M John Chapman
    Institut National de la Sante et de la Recherche Medicale INSERM, Hopital de la Pitie, Paris, France
    Curr Med Res Opin 20:1253-68. 2004
    ..03 mmol/L) in patients with CHD or with a high level of risk for CHD, including patients at high global risk with type 2 diabetes or the metabolic syndrome...
  33. ncbi Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study
    Naveed Sattar
    University Department of Pathological Biochemistry, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, Scotland, UK
    Circulation 108:414-9. 2003
    ..Information on the prospective association of this definition for coronary heart disease (CHD) and type 2 diabetes is currently limited...
  34. ncbi Lipid-lowering--translating evidence into benefits
    James Shepherd
    Department of Pathological Biochemistry, University of Glasgow Royal Infirmary, Glasgow, Scotland, UK
    Atheroscler Suppl 2:1-3. 2002
  35. ncbi Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals
    James Shepherd
    Department of Pathological Biochemistry, Royal Infirmary, University of Glasgow, Scotland, United Kingdom
    Am J Cardiol 91:11C-17C; discussion 17C-19C. 2003
    ..001). A total of 71% of patients treated with rosuvastatin 10 mg who had triglyceride levels > or =200 mg/dL met both their LDL cholesterol and their non-high-density lipoprotein cholesterol goals...
  36. ncbi Statin therapy in the elderly: does it make good clinical and economic sense?
    Moira M B Mungall
    Clinical Trials Unit, Glasgow Royal Infirmary, Glasgow, UK
    Drugs Aging 20:263-75. 2003
    ....
  37. ncbi Diabetes in tomorrow's world: dark clouds do have silver linings
    James Shepherd
    Institute of Biochemistry, Glasgow Royal Infirmary, Glasgow, UK
    Diabetes Obes Metab 4:351-5. 2002
  38. ncbi Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS)
    Leanne Streja
    Robertson Centre for Biostatistics, Glasgow University, Glasgow, Scotland, UK
    Am J Cardiol 90:731-6. 2002
    ..The absolute increment in HDL cholesterol is relatively constant across a range of baseline values, hence the percent change is largely a function of the starting value...
  39. ncbi Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy
    James Shepherd
    Glasgow Royal Infirmary, Glasgow, Scotland, UK
    Curr Med Res Opin 20:1571-8. 2004
    ..To evaluate the efficacy and safety of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy (HRT) in a randomized, double-blind, placebo-controlled trial...
  40. ncbi Safety of rosuvastatin
    James Shepherd
    Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland
    Am J Cardiol 94:882-8. 2004
    ..Rosuvastatin was well tolerated by a broad range of patients who had dyslipidemia, and its safety profile was similar to those of the comparator statins investigated in this extensive clinical program...
  41. ncbi Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease
    Marcello Tonelli
    Division of Nephrology and Division of Critical Care Medicine, University of Alberta, and Institute of Health Economics, Edmonton, Alberta, Canada
    Circulation 112:171-8. 2005
    ..We performed this analysis to determine whether pravastatin reduced the rate of kidney function loss over approximately 5 years in people with or at high risk for coronary disease...
  42. ncbi Lipids and CVD management: towards a global consensus
    Christie Ballantyne
    Arteriosclerosis and Lipoprotein Section, Baylor College of Medicine, Houston, TX, USA
    Eur Heart J 26:2224-31. 2005
    ..It also highlights areas where the guidelines differ and discusses points to consider when selecting the most appropriate recommendation...
  43. ncbi Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel
    James Shepherd
    Department of Vascular Biochemistry, Glasgow Royal Infirmary, Glasgow, UK
    Curr Med Res Opin 21:665-82. 2005
    ..Prolonged-release nicotinic acid with improved tolerability compared with previous formulations may have obvious advantages for use in this setting...
  44. ncbi Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    John C LaRosa
    State University of New York Health Science Center, Brooklyn, NY 11203, USA
    N Engl J Med 352:1425-35. 2005
    ..We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD)...
  45. ncbi Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003
    James Shepherd
    Atheroscler Suppl 5:115-23. 2004
  46. ncbi Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995
    James Shepherd
    Atheroscler Suppl 5:91-7. 2004
  47. ncbi [Hypercholesterolemia, the future of drug associations]
    James Shepherd
    Presse Med 33:1141-2. 2004
  48. ncbi Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study
    Naveed Sattar
    Division of Cardiovascular and Medical Sciences, Universityof Glasgow, Glasgow Royal Infirmary, Glasgow G31 2ER, Scotland, UK
    Diabetes 53:2855-60. 2004
    ..The simplicity of ALT measurement and its availability in routine clinical practice suggest that this enzyme activity could be included in future diabetes prediction algorithms...
  49. ncbi Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque
    Patrick W Serruys
    Thoraxcenter, Ba583, Erasmus MC, Rotterdam, Netherlands
    Circulation 118:1172-82. 2008
    ....
  50. doi Association of the 719Arg variant of KIF6 with both increased risk of coronary events and with greater response to statin therapy
    Olga Iakoubova
    J Am Coll Cardiol 51:2195; author reply 2195-6. 2008
  51. ncbi Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates
    Lorne F Forster
    Department of Pathological Biochemistry, Glasgow Royal Infirmary University NHS Trust, 4th Floor, Queen Elizabeth Building 10 Alexandra Parade, Glasgow, G31 2ER, Scotland, UK
    Atherosclerosis 164:129-45. 2002
    ..This leads to a substantial, and approximately equivalent, percentage reduction in plasma triglyceride and LDL cholesterol...
  52. ncbi Regulation of small dense LDL concentration in Korean and Scottish men and women
    Hong Keun Cho
    Department of Internal Medicine, Medical College, Ewha Women s University, Seoul, Republic of Korea
    Atherosclerosis 164:187-93. 2002
    ....
  53. ncbi Combined lipid lowering drug therapy for the effective treatment of hypercholesterolaemia
    James Shepherd
    Eur Heart J 24:685-9. 2003
  54. ncbi Metabolic syndrome and diabetes mellitus
    W E Feeman
    Circulation 109:E23. 2004
  55. ncbi Special report: Highlights of the 75th European Atherosclerosis Society congress
    James Shepherd
    Department of Pathological Biochemistry, University of Glasgow, Royal Infirmary, Glasgow, Scotland
    Atherosclerosis 181:S1-S7. 2005